Lupin Limited, a global leader in pharmaceuticals, has announced a strategic shift toward developing respiratory inhalers with propellants that have near-zero global warming potential (GWP). This initiative aims to provide patients with pressurized metered dose inhalers (pMDIs) that maintain the same high standards of efficacy and safety while significantly reducing their environmental footprint. The move aligns with European regulatory standards and Lupin’s broader goal of lowering its carbon emissions.
Professor Richard Dekhuijzen, a pulmonology expert from Radboud University Medical Center in the Netherlands, highlighted the dual benefits of this development: “The introduction of inhalers with near-zero global warming potential will not only minimize environmental impact but also ensure availability for patients who need these inhalers and cannot use dry powder alternatives.”
Vinita Gupta, Lupin’s CEO, added, “Our commitment to asthma patients worldwide drives us to focus on sustainable healthcare innovations. This ensures that those using our pMDIs can rely on treatments that are both effective and environmentally conscious.”
Innovation is central to Lupin’s approach, with ongoing improvements across projects, processes, and products. In the respiratory sector, the company’s strategy includes an expanded inhalation portfolio, accelerated development of pipeline products, and the early adoption of green propellant technologies.
By replacing standard propellants with near-zero GWP alternatives, Lupin aims to reinforce its position as a responsible leader in the pharmaceutical industry, dedicated to addressing environmental challenges for the benefit of patients and communities alike.
